{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:51:11Z","timestamp":1782247871793,"version":"3.54.5"},"reference-count":180,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HR22C1363"],"award-info":[{"award-number":["HR22C1363"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["HCRI 23028"],"award-info":[{"award-number":["HCRI 23028"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2023-00207920"],"award-info":[{"award-number":["RS-2023-00207920"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2020R1A5A2031185"],"award-info":[{"award-number":["2020R1A5A2031185"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2020R1A2C2010098"],"award-info":[{"award-number":["2020R1A2C2010098"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2021R1A2B5B0100214911"],"award-info":[{"award-number":["2021R1A2B5B0100214911"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2018R1A5A2024181"],"award-info":[{"award-number":["2018R1A5A2024181"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003668","name":"Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003624","name":"Ministry of Agriculture, Food and Rural Affairs","doi-asserted-by":"publisher","award":["322092\u20134"],"award-info":[{"award-number":["322092\u20134"]}],"id":[{"id":"10.13039\/501100003624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019780","name":"Chonnam National University Hwasun Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014189","name":"Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27892","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:48:52Z","timestamp":1710337732000},"page":"e27892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring cellular immunotherapy platforms in multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"given":"Manh-Cuong","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Tan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Dinh-Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodirjon","family":"Ruzimurodov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Hung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27892_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"111","author":"Jung","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3904\/kjim.2018.325","article-title":"Cellular immunotherapy in multiple myeloma","volume":"34","author":"Vo","year":"2019","journal-title":"Korean J. Intern. Med. (Engl. Ed.)"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27892_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27892_bib5","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12185-020-02833-w","article-title":"Fukuoka Blood and Marrow Transplantation Group. Phase I\/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma","volume":"111","author":"Mori","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.seminhematol.2009.02.006","article-title":"The role of high-dose therapy with autologous stem cell support in the era of novel agents","volume":"46","author":"Attal","year":"2009","journal-title":"Semin. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2009.07649.x","article-title":"Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma","volume":"145","author":"Lonial","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib137","unstructured":"Richardson, Paul, G. A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed\/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA. NCT02064387. ClinicalTrials.gov."},{"key":"10.1016\/j.heliyon.2024.e27892_bib138","unstructured":"Munshi NC. A Phase I\/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects with Relapsed or Relapsed\/Refractory Multiple Myeloma. NCT01001442. ClinicalTrials.gov."},{"key":"10.1016\/j.heliyon.2024.e27892_bib139","unstructured":"Nanjing Leads Biolabs Co., L. A Phase I\/II Clinical Trial of LBL-034 in Patients with Relapsed Refractory Multiple Myeloma. NCT06049290. ClinicalTrials.gov."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib103","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e27892_bib104","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib140","unstructured":"Shenzhen Pregene Biopharma, Clinical Study of the Safety and Efficacy of BCMA CAR-NK. NCT05652530. Clinicaltrials.gov."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib29","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e27892_bib141","unstructured":"Nanjing Legend Biotech Co. LCAR-B38M Cells in Treating Relapsed\/Refractory (R\/R) Multiple Myeloma (LEGEND-2). ClinicalTrials.gov. ID NCT03090659."},{"key":"10.1016\/j.heliyon.2024.e27892_bib142","unstructured":"2seventy bio. Study of Bb21217 in Multiple Myeloma. NCT03274219. ClinicalTrials.gov."},{"key":"10.1016\/j.heliyon.2024.e27892_bib143","unstructured":"Janssen Research & Development, LLC. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1). ClinicalTrials.gov Identifier: NCT03548207."},{"key":"10.1016\/j.heliyon.2024.e27892_bib144","unstructured":"National Cancer Institute (NCI). Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma. ClinicalTrials.gov. ID NCT02215967."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib25","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e27892_bib145","unstructured":"Juno Therapeutics, a Subsidiary of Celgene. Study Evaluating the Safety and Efficacy of JCARH125 in Subjects with Relapsed And\/or Refractory Multiple Myeloma (EVOLVE). ClinicalTrials.gov. ID NCT03430011."},{"key":"10.1016\/j.heliyon.2024.e27892_bib146","unstructured":"National Heart, Lung, and Blood Institute (NHLBI). Dendritic Cell\/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401). ClinicalTrials.gov. ID NCT02728102."},{"key":"10.1016\/j.heliyon.2024.e27892_bib147","unstructured":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Activated White Blood Cells with ASCT for Newly Diagnosed Multiple Myeloma. NCT00566098. ClinicalTrials.gov."},{"key":"10.1016\/j.heliyon.2024.e27892_bib148","unstructured":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma. NCT01858558. ClinicalTrials.gov."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e27892_bib121","doi-asserted-by":"crossref","first-page":"41538","DOI":"10.18632\/oncotarget.14582","article-title":"A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e27892_bib149","unstructured":"Biohaven Pharmaceuticals, Inc. Autologous Memory-like NK Cell Therapy with BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients. NCT04634435. ClinicalTrials.gov."},{"key":"10.1016\/j.heliyon.2024.e27892_bib150","unstructured":"Hospital Universitario 12 de Octubre, M., Spain, Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma. NCT02481934. ClinicalTrials.gov."},{"issue":"16_suppl","key":"10.1016\/j.heliyon.2024.e27892_bib79","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2022.40.16_suppl.8009","article-title":"Phase II study of umbilical cord blood\u2013derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM)","volume":"40","author":"Ali Srour","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib151","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1182\/blood-2022-159289","article-title":"Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma","volume":"140","author":"Cao","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib152","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib153","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib154","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib155","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3324\/haematol.2021.280169","article-title":"Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma","volume":"107","author":"Harush","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib156","doi-asserted-by":"crossref","first-page":"e1274","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib157","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib21","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib22","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib158","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e27892_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1275076","article-title":"Adoptive NK cell therapy - a beacon of hope in multiple myeloma treatment","volume":"13","author":"Vu","year":"2023","journal-title":"Front. Oncol."},{"issue":"705","key":"10.1016\/j.heliyon.2024.e27892_bib159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"288","key":"10.1016\/j.heliyon.2024.e27892_bib43","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib47","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res."},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib52","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2019-130629","article-title":"Superior efficacy of CAR-T cells using marrow-infiltrating lymphocytes (MILsTM) as compared to peripheral blood lymphocytes (PBLs)","volume":"134","author":"Lutz","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib160","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/blood-2018-99-118580","article-title":"Marrow-infiltrating lymphocytes (MILs) provide a robust platform for CAR-T cell therapy","volume":"132","author":"Lutz","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib161","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cells11030392","article-title":"Harnessing the potential of NK cell-based immunotherapies against multiple myeloma","volume":"11","author":"Reina-Ortiz","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib162","first-page":"1","article-title":"Antibody-drug conjugate therapies in multiple myeloma-what's next on the horizon?","volume":"3","author":"Hartley-Brown","year":"2022","journal-title":"Explor Target Antitumor Ther."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27892_bib163","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an anti-CD38\/attenuated ifn\u03b1 fusion protein, has clinical activity and modulates the ifn\u03b1 receptor (IFNAR) pathway in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"issue":"13_Supplement","key":"10.1016\/j.heliyon.2024.e27892_bib165","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1538-7445.AM2019-2384","article-title":"Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma","volume":"79","author":"Willert","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib166","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.clml.2019.09.252","article-title":"CD46 antibody drug conjugate impedes myeloma engraftment in patient-derived xenografts","volume":"19","author":"VanWyngarden","year":"2019","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib167","first-page":"5329","article-title":"Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC)","volume":"134","author":"Shah","year":"2019","journal-title":"STRO-001, in Patients with Advanced B-Cell Malignancies"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib168","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib169","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e27892_bib170","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e27892_bib171","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","article-title":"Randomized phase II trial of dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: bmt ctn 1401","volume":"29","author":"Chung","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27892_bib172","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3390\/cancers14174249","article-title":"T-Cell-Based cellular immunotherapy of multiple myeloma: current developments","volume":"14","author":"Simmons","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e27892_bib173","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/OTT.S370880","article-title":"Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives","volume":"16","author":"Shrivastava","year":"2023","journal-title":"OncoTargets Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib174","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/biomedicines9101422","article-title":"Novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells effectively target multiple myeloma","volume":"9","author":"Golubovskaya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.heliyon.2024.e27892_bib175","unstructured":"M.S.K.C.C. Phase I Trial of Concurrent Administration of GPRC5D Targeted CAR T Cell MCARH109 and BCMA Targeted CAR T Cell MCARH125 in Patients with Relapsed or Refractory Multiple Myeloma. NCT05431608. ClinicalTrials.gov."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib176","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib177","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib178","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib179","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2022-170501","article-title":"FT555: off-the-shelf CAR-NK cell therapy Co-targeting GPRC5D and CD38 for the treatment of multiple myeloma","volume":"140","author":"Reiser","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib180","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1182\/blood-2022-166167","article-title":"Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and \u03b3-secretase inhibitors","volume":"140","author":"Motais","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e27892_bib12","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"issue":"10254","key":"10.1016\/j.heliyon.2024.e27892_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.heliyon.2024.e27892_bib16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e27892_bib20","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27892_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e27892_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mayocpiqo.2019.12.006","article-title":"A graduate-level interdisciplinary curriculum in CAR-T cell therapy","volume":"4","author":"Sterner","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.heliyon.2024.e27892_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The pharmacology of T cell therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e27892_bib36","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","article-title":"Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression","volume":"28","author":"Huang","year":"2005","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/PPO.0000000000000158","article-title":"Endogenous T-cell therapy: clinical experience","volume":"21","author":"Yee","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.heliyon.2024.e27892_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2016.00051","article-title":"Bone marrow T cells and the integrated functions of recirculating and tissue-resident memory T cells","volume":"7","author":"Di Rosa","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/ITT.S305432","article-title":"The cancer-immunity cycle in multiple myeloma","volume":"10","author":"Casey","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.heliyon.2024.e27892_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fimmu.2016.00112","article-title":"Marrow-infiltrating lymphocytes - role in biology and cancer therapy","volume":"7","author":"Borrello","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593848","article-title":"Synthetic TILs: engineered tumor-infiltrating lymphocytes with improved therapeutic potential","volume":"10","author":"Jim\u00e9nez-Reinoso","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.it.2005.04.011","article-title":"The bone marrow: a nest for migratory memory T cells","volume":"26","author":"Di Rosa","year":"2005","journal-title":"Trends Immunol."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e27892_bib48","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood.V128.22.4552.4552","article-title":"Persistence of non gene-modified adoptively transferred marrow infiltrating lymphocytes (MILs) more than five years post transfer","volume":"128","author":"Noonan","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib49","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib50","first-page":"1","article-title":"Ciltacabtagene autoleucel for the treatment of multiple myeloma","volume":"59","author":"Sarah","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.heliyon.2024.e27892_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e27892_bib53","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1182\/blood-2023-188428","article-title":"Anti-BCMA dual epitope-binding CAR-marrow infiltrating lymphocytes (MILs) could offer a potent innovative immunotherapeutic tool against multiple myeloma","volume":"142","author":"Vo","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib56","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib57","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood-2019-126818","article-title":"Safety and preliminary clinical activity of REGN5458, an anti-bcma x anti-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e27892_bib58","series-title":"Phase 1\/2 Study of REGN5458 in Adult Patients with Relapsed or Refractory Multiple Myeloma (LINKER-MM1)","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e27892_bib59","article-title":"TeneoOne inc. (responsible party). A study of TNB-383B in participants with relapsed or refractory multiple myeloma","volume":"NCT03933735","year":"2023","journal-title":"ClinicalTrials.gov ID"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib60","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e27892_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27892_bib64","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.heliyon.2024.e27892_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","article-title":"Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned","volume":"108","author":"Can","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib66","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","article-title":"CAR-T cells and combination therapies: what's next in the immunotherapy revolution?","volume":"129","author":"Ramello","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib67","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib68","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib69","first-page":"265","article-title":"The impact of NK cell-based therapeutics for the treatment of lung cancer for biologics: targets and therapy","volume":"15","author":"Hamilton","year":"2021","journal-title":"Biologics"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e27892_bib70","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3324\/haematol.2021.279930","article-title":"The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells","volume":"108","author":"Richardson","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002958","article-title":"Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib73","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27892_bib74","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jcyt.2022.05.004","article-title":"Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer","volume":"24","author":"Jung","year":"2022","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib75","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00262-022-03322-1","article-title":"Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model","volume":"72","author":"Thangaraj","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib76","article-title":"Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma","volume":"3","author":"Nahi","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.heliyon.2024.e27892_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib81","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27892_bib82","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1083462","article-title":"Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27892_bib85","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.heliyon.2024.e27892_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684561","article-title":"Mechanisms of action of the new antibodies in use in multiple myeloma","volume":"11","author":"Romano","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27892_bib87","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2024.e27892_bib88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e27892_bib89","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib90","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27892_bib92","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib93","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","article-title":"Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors","volume":"6","author":"Oei","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib94","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"12","author":"Sun","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib95","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/aps.2015.41","article-title":"Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib96","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib98","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4054815","article-title":"Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies","volume":"2018","author":"Matosevic","year":"2018","journal-title":"J Immunol Res"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib99","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27892_bib100","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib101","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1472187","article-title":"A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells","volume":"7","author":"Kim","year":"2018","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27892_bib106","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4049\/jimmunol.1100016","article-title":"CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment","volume":"187","author":"Nair","year":"2011","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27892_bib107","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e27892_bib109","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1286-4579(99)00256-7","article-title":"TGF-beta1 regulation of dendritic cells","volume":"1","author":"Strobl","year":"1999","journal-title":"Microb. Infect."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","article-title":"Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming","volume":"198","author":"MartIn-Fontecha","year":"2003","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib112","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41401-020-0415-5","article-title":"Ex vivo pulsed dendritic cell vaccination against cancer","volume":"41","author":"Gu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt.09.78","article-title":"Personalized dendritic cell-based tumor immunotherapy","volume":"2","author":"Janikashvili","year":"2010","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib114","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27892_bib115","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3389\/fimmu.2018.01798","article-title":"Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model","volume":"9","author":"Vo","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27892_bib116","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.heliyon.2024.e27892_bib117","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exphem.2016.11.004","article-title":"Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma","volume":"46","author":"Vo","year":"2017","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-020-02654-0","article-title":"Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma","volume":"70","author":"Chu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2024.e27892_bib119","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fimmu.2018.01370","article-title":"Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma","volume":"9","author":"Vo","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib120","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","article-title":"Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects","volume":"108","author":"Titzer","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e27892_bib123","article-title":"Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib124","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2217\/imt.10.56","article-title":"Enhancement of dendritic cells as vaccines for cancer","volume":"2","author":"Turnis","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.heliyon.2024.e27892_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101413","article-title":"Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma","volume":"20","author":"Chu","year":"2022","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27892_bib127","article-title":"Effect of CRISPR\/Cas9-Edited PD-1\/PD-L1 on tumor immunity and immunotherapy","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/biom14010083","article-title":"Harnessing nanotechnology: emerging strategies for multiple myeloma therapy","volume":"14","author":"Yang","year":"2024","journal-title":"Biomolecules"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e27892_bib129","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27892_bib130","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2014.27","article-title":"Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy","volume":"28","author":"Berenson","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27892_bib131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","article-title":"Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells","volume":"32","author":"Eggermont","year":"2014","journal-title":"Trends Biotechnol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27892_bib132","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27892_bib133","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e27892_bib134","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.0400880101","article-title":"Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137","volume":"101","author":"Yang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27892_bib135","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/1078-0432.CCR-06-1905","article-title":"Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell","volume":"13","author":"Butler","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27892_bib136","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2005-05-2073","article-title":"Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity","volume":"107","author":"Hirano","year":"2006","journal-title":"Blood"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024039239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024039239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:35:38Z","timestamp":1782246938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024039239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024039239"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27892","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring cellular immunotherapy platforms in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27892"}}